These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 34771734)

  • 21. Outcomes of patients with detectable CMV DNA at randomization in the phase III trial of letermovir for the prevention of CMV infection in allogeneic hematopoietic cell transplantation.
    Marty FM; Ljungman PT; Chemaly RF; Wan H; Teal VL; Butterton JR; Yeh WW; Leavitt RY; Badshah CS
    Am J Transplant; 2020 Jun; 20(6):1703-1711. PubMed ID: 31883426
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effective CMV prophylaxis with high-dose valaciclovir in allogeneic hematopoietic stem-cell recipients at a high risk of CMV infection.
    Douglas G; Yong MK; Tio SY; Chau M; Prabahran A; Sasadeusz J; Slavin M; Ritchie D; Chee L
    Transpl Infect Dis; 2023 Feb; 25(1):e13994. PubMed ID: 36413495
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mortality in recipients of allogeneic haematopoietic cell transplantation in the era of cytomegalovirus primary prophylaxis: a single-centre retrospective experience.
    Febres-Aldana A; Khawaja F; Morado-Aramburo O; Shigle TL; Rondon G; Sassine J; Spallone A; Srinivasan K; Ramdial J; Alousi A; Champlin R; Chen G; Daher M; Rezvani K; Ariza-Heredia EJ; Shpall EJ; Chemaly RF
    Clin Microbiol Infect; 2024 Jun; 30(6):803-809. PubMed ID: 38460821
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Letermovir prophylaxis for cytomegalovirus reactivation in allogeneic hematopoietic cell transplant recipients: Single center Canadian data.
    Pang I; Chen P; Trinh GV; Remberger M; Novitzky-Basso I; Gerbitz A; Kim DD; Kumar R; Lam W; Law AD; Lipton JH; Viswabandya A; Pasic I; Mattsson J; Michelis FV
    Eur J Haematol; 2024 Feb; 112(2):301-309. PubMed ID: 37830403
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Letermovir as secondary prophylaxis of cytomegalovirus infection after allogeneic hematopoietic cell transplantation: A single center experience.
    Desai N; Pasic I; Law AD; Lam W; Gerbitz A; Viswabandya A; Kim DD; Kumar R; Mattsson J; Novitzky-Basso I; Michelis FV
    Eur J Haematol; 2024 Jun; ():. PubMed ID: 39031870
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of letermovir prophylaxis in CMV reactivation and disease after allogenic hematopoietic cell transplantation: a real-world, observational study.
    Brusosa M; Ruiz S; Monge I; Solano MT; Rosiñol L; Esteve J; Carreras E; Marcos MÁ; Riu G; Carcelero E; Martinez C; Fernández-Avilés F; Rovira M; Suárez-Lledó M; Salas MQ
    Ann Hematol; 2024 Feb; 103(2):609-621. PubMed ID: 37957371
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Oral Brincidofovir for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation.
    Marty FM; Winston DJ; Chemaly RF; Mullane KM; Shore TB; Papanicolaou GA; Chittick G; Brundage TM; Wilson C; Morrison ME; Foster SA; Nichols WG; Boeckh MJ;
    Biol Blood Marrow Transplant; 2019 Feb; 25(2):369-381. PubMed ID: 30292744
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Letermovir for the prevention of cytomegalovirus infection in adult cytomegalovirus-seropositive hematopoietic stem cell transplant recipients.
    Foolad F; Aitken SL; Chemaly RF
    Expert Rev Clin Pharmacol; 2018 Oct; 11(10):931-941. PubMed ID: 30004790
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prophylactic letermovir decreases cytomegalovirus reactivation after stem cell transplantation: a single-center real-world evidence study.
    Serio B; Giudice V; Guariglia R; Fontana R; Pezzullo L; Martorelli MC; Ferrara I; Mettivier L; D'Addona M; Vaccaro E; Langella M; Selleri C
    Infez Med; 2021 Mar; 29(1):102-113. PubMed ID: 33664179
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Letermovir prophylaxis is effective in preventing cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation: single-center real-world data.
    Derigs P; Radujkovic A; Schubert ML; Schnitzler P; Schöning T; Müller-Tidow C; Hegenbart U; Schönland SO; Luft T; Dreger P; Schmitt M
    Ann Hematol; 2021 Aug; 100(8):2087-2093. PubMed ID: 33270162
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of Primary Letermovir Prophylaxis Versus Preemptive Antiviral Therapy for Cytomegalovirus on Economic and Clinical Outcomes after Hematopoietic Cell Transplantation.
    Tan CA; Palen L; Su Y; Li Y; Gennarelli RL; Perales MA; Cohen N; Papanicolaou GA; Shah GL; Seo SK
    Transplant Cell Ther; 2024 Aug; 30(8):792.e1-792.e12. PubMed ID: 38838781
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cytomegalovirus breakthrough and resistance during letermovir prophylaxis.
    Perchetti GA; Biernacki MA; Xie H; Castor J; Joncas-Schronce L; Ueda Oshima M; Kim Y; Jerome KR; Sandmaier BM; Martin PJ; Boeckh M; Greninger AL; Zamora D
    Bone Marrow Transplant; 2023 Apr; 58(4):430-436. PubMed ID: 36693927
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cytomegalovirus (CMV) Cell-Mediated Immunity and CMV Infection After Allogeneic Hematopoietic Cell Transplantation: The REACT Study.
    Chemaly RF; El Haddad L; Winston DJ; Rowley SD; Mulane KM; Chandrasekar P; Avery RK; Hari P; Peggs KS; Kumar D; Nath R; Ljungman P; Mossad SB; Dadwal SS; Blanchard T; Shah DP; Jiang Y; Ariza-Heredia E
    Clin Infect Dis; 2020 Dec; 71(9):2365-2374. PubMed ID: 32076709
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patterns of CMV infection after letermovir withdrawal in recipients of posttransplant cyclophosphamide-based transplant.
    Lin A; Brown S; Chinapen S; Lee YJ; Seo SK; Ponce DM; Shahid Z; Giralt S; Papanicolaou GA; Perales MA; Shaffer BC
    Blood Adv; 2023 Dec; 7(23):7153-7160. PubMed ID: 37906513
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The promising efficacy of a risk-based letermovir use strategy in CMV-positive allogeneic hematopoietic cell recipients.
    Sourisseau M; Faure E; Béhal H; Chauvet P; Srour M; Capes A; Coiteux V; Magro L; Alfandari S; Alidjinou EK; Simon N; Vuotto F; Karam M; Faure K; Yakoub-Agha I; Beauvais D
    Blood Adv; 2023 Mar; 7(5):856-865. PubMed ID: 36350752
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Letermovir Primary Prophylaxis in High-Risk Hematopoietic Cell Transplant Recipients: A Matched Cohort Study.
    Royston L; Royston E; Masouridi-Levrat S; Vernaz N; Chalandon Y; Van Delden C; Neofytos D
    Vaccines (Basel); 2021 Apr; 9(4):. PubMed ID: 33921218
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-World Outcomes Associated With Letermovir Use for Cytomegalovirus Primary Prophylaxis in Allogeneic Hematopoietic Cell Transplant Recipients: A Systematic Review and Meta-analysis of Observational Studies.
    Vyas A; Raval AD; Kamat S; LaPlante K; Tang Y; Chemaly RF
    Open Forum Infect Dis; 2023 Jan; 10(1):ofac687. PubMed ID: 36726548
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lower Incidence of Cytomegalovirus Reactivation Following Post-Transplantation Cyclophosphamide HLA-Mismatched Unrelated Donor Transplantation.
    Camargo JF; Ebisu Y; Jimenez-Jimenez A; Natori Y; Moroz I; Morris MI; Alencar M; Anderson AD; Lekakis L; Beitinjaneh A; Goodman M; Wang T; Pereira D; Komanduri KV
    Transplant Cell Ther; 2021 Dec; 27(12):1017.e1-1017.e7. PubMed ID: 34543769
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CMV Infection After Letermovir Primary Prophylaxis Discontinuation in Allogeneic Hematopoietic Cell Transplant Recipients.
    Chavaz L; Royston L; Masouridi-Levrat S; Mamez AC; Giannotti F; Morin S; Van Delden C; Chalandon Y; Neofytos D
    Open Forum Infect Dis; 2023 Apr; 10(4):ofad169. PubMed ID: 37125233
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.